Literature DB >> 18028268

Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review.

Beau M Hawkins1, Mazen Abu-Fadel, Sara K Vesely, James N George.   

Abstract

BACKGROUND: Autopsy studies consistently demonstrate cardiac involvement in thrombotic thrombocytopenic purpura (TTP), but clinical evidence for cardiac abnormalities is rarely reported. STUDY DESIGN AND METHODS: This systematic review addresses the apparent discrepancy between autopsy and clinical data. English language articles were identified by keywords for both TTP and for cardiac symptoms, testing, or events. Patients were analyzed if they were more than 10 years old with idiopathic TTP.
RESULTS: Thirty articles were identified that described 111 eligible patients: 20 case reports described 27 patients, 9 retrospective cohort studies described 74 patients, and 1 prospective cohort study described 10 patients. Cardiac events included infarction (26 patients), congestive failure (17), arrhythmias (10), cardiogenic shock (6), and sudden cardiac death (8). Mortality was assessed in 101 patients: 55 died, and 48 autopsies were described. All demonstrated cardiac microvascular thrombi, hemorrhage, and/or necrosis. Follow-up information was reported in only 6 of the 16 patients who survived a cardiac event (follow-up duration, 10 days-2 years; median, 7 weeks).
CONCLUSIONS: The frequency and sequelae of clinical cardiac abnormalities in TTP cannot be accurately assessed because most patients were described in reports of few selected patients; many patients were reported before the availability of effective treatment for TTP and sensitive tests for cardiac involvement. Continuing case reports and cohort studies, however, suggest that cardiac abnormalities may be important and often unrecognized causes of mortality and morbidity in patients with TTP. Prospective studies are needed to determine if cardiac therapy can improve survival and long-term outcomes of patients with TTP.

Entities:  

Mesh:

Year:  2007        PMID: 18028268     DOI: 10.1111/j.1537-2995.2007.01534.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  26 in total

1.  Heart transplantation for acute cardiac failure caused by thrombotic thrombocytopenic purpura (TTP).

Authors:  Michel Wolff; Richard Dorent; Agnès Veyradier; Lydia Deschamps; Richard Raffoul
Journal:  Intensive Care Med       Date:  2012-07-07       Impact factor: 17.440

2.  ST-segment elevation myocardial infarction treated with thrombolytic therapy in a patient with thrombotic thrombocytopenic purpura.

Authors:  Jacob A Doll; Jacob P Kelly
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

3.  Transfer of ADAMTS13 antibody-mediated thrombotic thrombocytopenic purpura via kidney transplantation.

Authors:  Lara Zafrani; Charlotte Dekimpe; Bérangère S Joly; Elien Roose; Fabienne Fieux; Elie Azoulay; Marie-Noëlle Peraldi; Antoine Durrbach; Paul Coppo; Karen Vanhoorelbeke; Agnès Veyradier
Journal:  Haematologica       Date:  2019-02-28       Impact factor: 9.941

4.  Does this patient with thrombotic thrombocytopenic purpura have a cardiac involvement?

Authors:  Lara Zafrani; Lene Russell; Elie Azoulay
Journal:  Intensive Care Med       Date:  2018-06-04       Impact factor: 17.440

5.  Causes and risk factors of death in patients with thrombotic microangiopathies.

Authors:  Vincent Peigne; Pierre Perez; Matthieu Resche Rigon; Eric Mariotte; Emmanuel Canet; Jean-Paul Mira; Paul Coppo; Agnès Veyradier; Elie Azoulay
Journal:  Intensive Care Med       Date:  2012-07-14       Impact factor: 17.440

6.  Macrovascular thrombosis in critically ill patients with thrombotic micro-angiopathies.

Authors:  Laurent Camous; Agnès Veyradier; Michael Darmon; Lionel Galicier; Eric Mariotte; Emmanuel Canet; Nathalie Parquet; Élie Azoulay
Journal:  Intern Emerg Med       Date:  2012-10-07       Impact factor: 3.397

Review 7.  [Thrombotic-thrombocytopenic purpura].

Authors:  M Hellmann; M Hallek; I Scharrer
Journal:  Internist (Berl)       Date:  2010-09       Impact factor: 0.743

8.  Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.

Authors:  Cassandra C Deford; Jessica A Reese; Lauren H Schwartz; Jedidiah J Perdue; Johanna A Kremer Hovinga; Bernhard Lämmle; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

9.  Unresponsive thrombotic thrombocytopenic purpura in critically ill adults.

Authors:  Eric Mariotte; Alice Blet; Lionel Galicier; Michael Darmon; Nathalie Parquet; Etienne Lengline; David Boutboul; Emmanuel Canet; Richard Traineau; Benoît Schlemmer; Agnès Veyradier; Elie Azoulay
Journal:  Intensive Care Med       Date:  2013-04-03       Impact factor: 17.440

10.  Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice.

Authors:  Simon F De Meyer; Alexander S Savchenko; Michael S Haas; Daphne Schatzberg; Michael C Carroll; Alexandra Schiviz; Barbara Dietrich; Hanspeter Rottensteiner; Friedrich Scheiflinger; Denisa D Wagner
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.